“…There was a protective effect of 5-ASA on CRC in UC patients, with an OR of 0.52 (95% CI: 0.29-0.95; p = 0.03), but this effect was not seen among CD patients (OR 0.62, 95% CI: 0.27-1.40; p = 0.25). Main studies that evaluated the relationship between 5-ASA treatment and CRC risk in IBD are summarized in table 1 [11,15,24,25,26,27,28,32,33,34,35,36,37,38,39,40,41,42,43,44]. …”